[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cradle-cap\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cradle-cap":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":5},"100659198","triderm-ds-crema-normalizzante-for-neonatal-hyperseborrhea-cradle-cap-and-associated-cutaneous-manifestations-of-mild-to-moderate-seborrheic-dermatitis-in-children-aged-0-to-3-years-100659198",false,"NCT07860788","TRIDERM D.S. Crema Normalizzante for Neonatal Hyperseborrhea (Cradle Cap) and Associated Cutaneous Manifestations of Mild-to-Moderate Seborrheic Dermatitis in Children Aged 0 to 3 Years","Prospective, Interventional, Single-Center, Single-Arm Clinical Study to Evaluate the Clinical Improvement of Neonatal Hyperseborrhea (\"Cradle Cap\"), Including Potential Cutaneous Manifestations Associated With Mild-to-Moderate Seborrheic Dermatitis, and the Cutaneous Tolerability of the Cosmetic Product TRIDERM D.S. Crema Normalizzante.","Inclusion Criteria:\n\n* Age from 0 to 3 years.\n* Good general health.\n* Clinical diagnosis of neonatal hyperseborrhea (\"cradle cap\"), including possible cutaneous manifestations associated with mild-to-moderate seborrheic dermatitis.\n* No use of keratolytic, anti-inflammatory, or antifungal treatments within the 15 days prior to enrollment.\n* Written informed consent provided by the participant's parent(s) or legal guardian.\n\nExclusion Criteria:\n\n* Presence of other concomitant dermatological conditions that, in the Investigator's judgment, may interfere with the clinical assessment of the study.\n* Presence of seborrheic dermatitis of greater severity than that specified in the inclusion criteria.\n* Use of specific topical treatments (keratolytics, corticosteroids, or antifungals) on the affected areas within the 15 days prior to enrollment.\n* Participation in another clinical study within the 30 days prior to enrollment.\n* Known or suspected hypersensitivity to one or more components of the study product.","ALL","0 Years","3 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"NA","This clinical study aims to evaluate the effects of using the cosmetic product TRIDERM D.S. Crema Normalizzante in children aged 0 to 3 years with neonatal hyperseborrhea (\"cradle cap\"), potentially associated with manifestations of mild-to-moderate seborrheic dermatitis. The study will assess whether use of the product is associated with an improvement in the clinical signs of the condition, particularly scaling and erythema, and will evaluate its cutaneous tolerability. Caregiver-perceived improvement, as well as additional dermatological, photographic, and instrumental assessments, will also be considered.",[27,28],"Cradle Cap","Seborrheic Dermatitis",[30,31,32,33,34,35,36,37,38],"Neonatal hyperseborrhea","Infantile seborrheic dermatitis","Cradle cap","Scaling","Erythema","Pediatric dermatology","Cosmetic product","Cutaneous tolerability","TRIDERM D.S. Crema Normalizzante","NOT_YET_RECRUITING","2026-09-30",{"date":42,"type":43},"2026-10-06","ACTUAL",{"date":45,"type":21},"2026-10",{"date":47,"type":21},"2027-02",{"name":49,"class":50},"ICIM International S.r.l.","INDUSTRY"]